Ward Detwiler
Grosse Pointe, Michigan, United States
2K followers
500+ connections
Activity
-
“(Imagion) has secured IND clearance from the FDA in an achievement that is the company’s most important to date…” Click the link to read Pitt…
“(Imagion) has secured IND clearance from the FDA in an achievement that is the company’s most important to date…” Click the link to read Pitt…
Liked by Ward Detwiler
-
We are excited to announce that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed notice for the Company’s Investigational…
We are excited to announce that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed notice for the Company’s Investigational…
Liked by Ward Detwiler
-
Big news for Imagion yesterday! I couldn't be more proud of our whole team for getting us to this milestone. Our IND clearance and allowance for the…
Big news for Imagion yesterday! I couldn't be more proud of our whole team for getting us to this milestone. Our IND clearance and allowance for the…
Shared by Ward Detwiler
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
University of Michigan - Stephen M. Ross School of Business
-
-
Activities and Societies: -Revitalization & Business Initiative: VP of Corporate Outreach -Entrepreneur and Venture Club: Core Team -Ross Hockey Club -Ross Ski Club
-
-
-
More activity by Ward
-
I am so proud of our whole team for getting us to this point. A big milestone in bringing molecular MRI to millions of patients in need!
I am so proud of our whole team for getting us to this point. A big milestone in bringing molecular MRI to millions of patients in need!
Shared by Ward Detwiler
-
Exciting news from Imagion Biosystems: We've submitted our IND application to the FDA for a Phase 2 clinical trial of the MagSense® HER2 Imaging…
Exciting news from Imagion Biosystems: We've submitted our IND application to the FDA for a Phase 2 clinical trial of the MagSense® HER2 Imaging…
Liked by Ward Detwiler
-
Ward Detwiler and Bob Proulx are at RSNA 2025 in Chicago this week, connecting with radiologists and exploring strategic partnerships in molecular…
Ward Detwiler and Bob Proulx are at RSNA 2025 in Chicago this week, connecting with radiologists and exploring strategic partnerships in molecular…
Liked by Ward Detwiler
-
A study published in the Journal of the American Medical Association has revealed current MRI techniques correctly identify prostate cancer only ~60%…
A study published in the Journal of the American Medical Association has revealed current MRI techniques correctly identify prostate cancer only ~60%…
Liked by Ward Detwiler
-
We're honored to be featured in Stockhead alongside other ASX companies advancing early detection and care. Executive Chair Bob Proulx explains the…
We're honored to be featured in Stockhead alongside other ASX companies advancing early detection and care. Executive Chair Bob Proulx explains the…
Liked by Ward Detwiler
-
Check out this feature from The Market Bull highlighting recent developments in our MagSense® molecular MRI technology. $IBX
Check out this feature from The Market Bull highlighting recent developments in our MagSense® molecular MRI technology. $IBX
Liked by Ward Detwiler
-
Program Update: HER2 Breast Cancer Phase 2 Clinical Trial Advances We've completed manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent…
Program Update: HER2 Breast Cancer Phase 2 Clinical Trial Advances We've completed manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent…
Liked by Ward Detwiler
-
Recently we announced that Dr. Nina Webster was appointed to our Board as a Non-Executive Director, bringing over 30 years of experience in the…
Recently we announced that Dr. Nina Webster was appointed to our Board as a Non-Executive Director, bringing over 30 years of experience in the…
Liked by Ward Detwiler
-
More great news for Imagion this weekI I really appreciate the detailed dive that Pitt Street took into our company and the strides our team has…
More great news for Imagion this weekI I really appreciate the detailed dive that Pitt Street took into our company and the strides our team has…
Shared by Ward Detwiler
-
Pitt Street Research has released their market analysis on Imagion Biosystems, Ltd (ASX:IBX). The full report is available on Stocks Down Under (link…
Pitt Street Research has released their market analysis on Imagion Biosystems, Ltd (ASX:IBX). The full report is available on Stocks Down Under (link…
Liked by Ward Detwiler
Other similar profiles
Explore more posts
-
Eric Berry
If you’re building at the edge of healthcare innovation, you need to understand how the ground may be shifting beneath you. Averin Capital is hosting a rare conversation between some of the FDA's most influential legal minds of the past 50 years: Peter Hutt - former FDA Chief Counsel and one of the key architects behind the modern food and drug regulatory system. Dan Troy - former FDA Chief Counsel and top advisor to multiple life sciences companies and the U.S. government. Moderated by David Berry, Managing Partner at our firm and one of biotech’s most prolific company builders. They’ll unpack how the FDA’s approach is evolving—and what that means for startups trying to do something new. We’ll cover: • Where regulation is tightening or loosening • How to navigate ambiguity without getting derailed • What smart companies are doing now to get ahead of regulatory risk 🗓 Register here: https://lnkd.in/e-KDH36k This is one of those conversations that doesn’t happen often, but shapes how you think for years. Don’t miss it.
2 Comments -
SC Moatti
I’m excited to share that Angle Health, founded by former Palantir Technologies execs Tylon (Ty) W. and Anirban Gangopadhyay, has announced an oversubscribed Series B bringing total funding to nearly $200M. I’m proud to be an early investor and to have led this competitive round with the amazing team at Portage. Why we keep leaning in: - 26x revenue growth since the Series A - Serving 3,000+ employers across 44 states - 80%+ renewal rates Angle Health is rebuilding the healthcare benefits infrastructure for SMBs, who employ nearly half of America’s workforce but have historically been shut out of enterprise-grade coverage. Their AI-native platform helps predict risk and deliver better care at a sustainable cost. This is exactly the kind of product-driven, AI-native company we’re proud to support at Mighty Capital.
-
Ken Nelson
Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies ever. Time will tell if this massive consolidation ever gets completed or translates into real value — or if it's just another bet on scale.
3 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content